News & Events

Webinar: Translational Animal Models of Atopic Dermatitis (AD) for Preclinical Studies

Our webinar “Translational Animal Models of Atopic Dermatitis (AD) for Preclinical Studies" was live at 12PM EDT on March 27, 2024. About the webinar: Atopic…

Read more
Biocytogen Symposium 2024: New Targets, New Therapeutics

[embed]https://youtu.be/TPV_3gMmUvE?si=qgqV-_b_0euuhL5I[/embed] Thanks to all who joined us at the 2024 Biocytogen Symposium! Your participation made this event a tremendous success. Whether you joined us in person or…

Read more
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Beijing, China, February 19, 2024 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences,…

Read more
Webinar: Preclinical Pharmacology Services to Support Evaluation of Novel Cell & Gene Therapies

Our webinar “Preclinical Pharmacology Services to Support Evaluation of Novel Cell & Gene Therapies" was live at 12PM EST on February 28, 2024. About the…

Read more
Join us at Next-Gen Immuno-Oncology Conference: Feb 8-9

Join us at the MarketsandMarkets Next-Gen Immuno-Oncology Conference in San Diego, CA from February 8-9, 2024! We're excited to present "BioMice: Preclinical Oncology/Immuno-Oncology Models for…

Read more
Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Beijing, China – January 23, 2024 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of a new sub-brand, RenBiologicsTM, to…

Read more
Dr. Yuelei Shen Shared His Insights During Investment Reports/Newsweek Interview

Source: Investment Reports This interview, together with other interviews with the industry’s leading figures, will be published in the second edition of The New Era…

Read more
Join us at PepTalk 2024: Jan 16-19

Join us at booth #717 at PepTalk 2024 from January 16-19 in San Diego, CA! Dr. Frank An, Senior Director, Antibody Therapeutics will be presenting…

Read more
Biocytogen’s YH008 Greater China Licensee Chipscreen NewWay Announces First-Patient-In for Bispecific Antibody NWY001, a Next-Gen Tumor Immunotherapy

Beijing, China, January 5, 2024 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) partner Chipscreen NewWay Biosciences (“Chipscreen NewWay”) achieved first-patient-in for a phase…

Read more
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

BEIJING, China and BOSTON, Massachusetts, USA---Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics,…

Read more
Back to top